Neurocrine Biosciences' Management Presents at Morgan Stanley Global Healthcare Conference - Transcript
http://seekingalpha.com/article/862811-neurocrine-biosciences-management-presents-at-morgan-stanley-global-healthcare-conference-transcript?source=yahoo
http://seekingalpha.com/article/862811-neurocrine-biosciences-management-presents-at-morgan-stanley-global-healthcare-conference-transcript?source=yahoo
Recent NBIX News
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 04/06/2026 11:39:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/06/2026 11:35:19 AM
- Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio • PR Newswire (US) • 04/06/2026 11:00:00 AM
- Neurocrine unveils first expert guidance for tardive dyskinesia care in long-term facilities • IH Market News • 03/26/2026 03:27:23 PM
- Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings • PR Newswire (US) • 03/26/2026 12:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/17/2026 09:56:51 PM
- Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer • PR Newswire (US) • 03/17/2026 08:05:00 PM
- Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum • PR Newswire (US) • 03/10/2026 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2026 11:18:36 PM
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in March • PR Newswire (US) • 02/24/2026 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 12:12:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:49:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:48:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:47:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:46:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:46:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:45:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:45:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:44:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2026 10:44:03 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/11/2026 09:03:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:02:00 PM
- Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 • PR Newswire (US) • 02/11/2026 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 11:22:45 PM

